Skip to main content

Table 1 Baseline characteristics and demographic information

From: Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy

Variable

Adult cohort n = 106

Pediatric cohort n = 19

Age at diagnosis (years)

Median

54

8

Range

21–93

2–17

Sex

Female

54 (51%)

9 (47%)

Male

52 (49%)

10 (53%)

Stage (TNM)

I

7 (7%)

4 (21%)

II

13 (12%)

-

III

26 (25%)

-

IV

56 (53%)

6 (32%)

Other (Non-TNM)

-

9 (47%)

Unknown

4 (3%)

-

Prior lines of systemic therapies

0–1

41 (38%)

11 (58%)

2–3

48 (45%)

5 (26%)

4 or more

18 (17%)

3 (16%)

Prior standard-of-care targeted therapy

 

11 (10%)

-